Levetiracetam is an anticonvulsant medication used as add-on therapy for the treatment of partial seizures in adults. It is an S-enantiomer of etiracetam, structurally similar to the prototypical nootropic drug piracetam. Levetiracetam's presumed novel mechanism includes binding to a synaptic vesicle protein, SV2A, which is believed to impede nerve conduction across synapses, reversal of zinc inhibition of y-aminobutyric acid (GABA) and glycine-gated currents and by partial inhibition of voltage-gated calcium channels [1].
展开▼
